INNT vs. SCPS, EVLO, CMRA, ARDS, STAB, AMPE, CLVR, EFTR, HSTO, and MTEM
Should you be buying Innovate Biopharmaceuticals stock or one of its competitors? The main competitors of Innovate Biopharmaceuticals include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), and Molecular Templates (MTEM). These companies are all part of the "medical" sector.
Innovate Biopharmaceuticals vs. Its Competitors
Scopus BioPharma (NASDAQ:SCPS) and Innovate Biopharmaceuticals (NASDAQ:INNT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.
5.9% of Innovate Biopharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 7.9% of Innovate Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Scopus BioPharma had 2 more articles in the media than Innovate Biopharmaceuticals. MarketBeat recorded 2 mentions for Scopus BioPharma and 0 mentions for Innovate Biopharmaceuticals. Scopus BioPharma's average media sentiment score of 0.00 equaled Innovate Biopharmaceuticals'average media sentiment score.
Scopus BioPharma has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Innovate Biopharmaceuticals has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500.
Summary
Scopus BioPharma beats Innovate Biopharmaceuticals on 4 of the 6 factors compared between the two stocks.
Get Innovate Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innovate Biopharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:INNT) was last updated on 7/5/2025 by MarketBeat.com Staff
